Home › Minerva Biotechnologies Licenses Sendai Virus Technology For Stem Cell Generation
 

Keywords :   


Minerva Biotechnologies Licenses Sendai Virus Technology For Stem Cell Generation

2015-09-02 07:10:05| drugdiscoveryonline News Articles

Minerva Biotechnologies and ID Pharma Co., Ltd. (formerly DNAVEC) announced recently that they have signed an agreement granting Minerva worldwide rights to use and commercialize their non-integrating Sendai virus vectors, together with Minerva’s proprietary technology, for generating Induced Pluripotent Stem (iPS) cells

Tags: technology cell generation virus

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
06.11Eastern North Pacific Tropical Weather Outlook
05.11Tropical Storm Rafael Graphics
05.11Tropical Storm Rafael Forecast Discussion Number 9
05.11Tropical Storm Rafael Wind Speed Probabilities Number 9
05.11Tropical Storm Rafael Public Advisory Number 9
05.11Summary for Tropical Storm Rafael (AT3/AL182024)
05.11Tropical Storm Rafael Forecast Advisory Number 9
05.11Delayed implementation of EID eartag rule requested
More »